Kelen Cristina Ribeiro Malmegrim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6846834/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2007, 297, 1568.	3.8	482
2	C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2009, 301, 1573.	3.8	370
3	Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Research and Therapy, 2019, 10, 131.	2.4	342
4	Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients. Bone Marrow Transplantation, 2015, 50, 380-389.	1.3	79
5	Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. Blood Advances, 2018, 2, 126-141.	2.5	71
6	Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes. Frontiers in Immunology, 2017, 8, 167.	2.2	65
7	Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation. Clinical Immunology, 2016, 169, 47-57.	1.4	55
8	Xenogeneic Mesenchymal Stromal Cells Improve Wound Healing and Modulate the Immune Response in an Extensive Burn Model. Cell Transplantation, 2016, 25, 201-215.	1.2	50
9	Dynamic changes of the Th17/Tc17 and regulatory T cell populations interfere in the experimental autoimmune diabetes pathogenesis. Immunobiology, 2013, 218, 338-352.	0.8	49
10	Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties. Stem Cell Research and Therapy, 2016, 7, 14.	2.4	46
11	Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and nonâ€canonical NFâ€rB signalling. Journal of Cellular and Molecular Medicine, 2012, 16, 1232-1244.	1.6	44
12	Bone Marrow Mesenchymal Stromal Cells Isolated from Multiple Sclerosis Patients have Distinct Gene Expression Profile and Decreased Suppressive Function Compared with Healthy Counterparts. Cell Transplantation, 2015, 24, 151-165.	1.2	44
13	Cultured Human Adipose Tissue Pericytes and Mesenchymal Stromal Cells Display a Very Similar Gene Expression Profile. Stem Cells and Development, 2015, 24, 2822-2840.	1.1	44
14	Therapeutic efficacy and biodistribution of allogeneic mesenchymal stem cells delivered by intrasplenic and intrapancreatic routes in streptozotocin-induced diabetic mice. Stem Cell Research and Therapy, 2015, 6, 31.	2.4	43
15	Autologous Hematopoietic Stem Cell Transplantation for Type 1 Diabetes. Annals of the New York Academy of Sciences, 2008, 1150, 220-229.	1.8	37
16	Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis. Bone Marrow Transplantation, 2018, 53, 1319-1327.	1.3	33
17	Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis. Clinical Science, 2015, 128, 111-120.	1.8	29
18	Recombinant anti-P protein autoantibodies isolated from a human autoimmune library: reactivity, specificity and epitope recognition. Cellular and Molecular Life Sciences, 2003, 60, 588-598.	2.4	26

#	Article	IF	CITATIONS
19	Plasma eicosanoid profiles determined by high-performance liquid chromatography coupled with tandem mass spectrometry in stimulated peripheral blood from healthy individuals and sickle cell anemia patients in treatment. Analytical and Bioanalytical Chemistry, 2016, 408, 3613-3623.	1.9	26
20	Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19. Stem Cell Reviews and Reports, 2021, 17, 71-93.	1.7	26
21	Up-regulation of <i>fas</i> and <i>fasL</i> pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation. Clinical and Experimental Immunology, 2012, 168, 291-302.	1.1	24
22	Mast cells control insulitis and increase Treg cells to confer protection against STZâ€induced type 1 diabetes in mice. European Journal of Immunology, 2015, 45, 2873-2885.	1.6	24
23	Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: From Mechanistic Insights to Biomarkers. Frontiers in Immunology, 2018, 9, 2602.	2.2	23
24	A single administration of human adipose tissue-derived mesenchymal stromal cells (MSC) induces durable and sustained long-term regulation of inflammatory response in experimental colitis. Clinical and Experimental Immunology, 2019, 196, 139-154.	1.1	23
25	Cytokine profile and lymphocyte subsets in type 2 diabetes. Brazilian Journal of Medical and Biological Research, 2016, 49, e5062.	0.7	21
26	Transcriptional profiling reveals intrinsic mRNA alterations in multipotent mesenchymal stromal cells isolated from bone marrow of newly-diagnosed type 1 diabetes patients. Stem Cell Research and Therapy, 2016, 7, 92.	2.4	21
27	Genes Related to Antiviral Activity, Cell Migration, and Lysis Are Differentially Expressed in CD4+T Cells in Human T Cell Leukemia Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis Patients. AIDS Research and Human Retroviruses, 2014, 30, 610-622.	0.5	20
28	Emerging Role of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Pathogenesis of Haematological Malignancies. Stem Cells International, 2019, 2019, 1-12.	1.2	19
29	Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation. Clinical and Experimental Immunology, 2017, 187, 383-398.	1.1	18
30	Haematopoietic stem cell transplantation for refractory Takayasu's arteritis. British Journal of Rheumatology, 2004, 43, 1308-1309.	2.5	17
31	Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies. Hematology, Transfusion and Cell Therapy, 2020, 42, 150-158.	0.1	16
32	Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives. Immunology Letters, 2020, 224, 1-11.	1.1	16
33	Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients. Rheumatology, 2021, 60, 5538-5548.	0.9	15
34	New Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell Replacement. Frontiers in Immunology, 2018, 9, 1086.	2.2	14
35	Caspase-mediated cleavage of the U snRNP-associated Sm-F protein during apoptosis. Cell Death and Differentiation, 2003, 10, 570-579.	5.0	12
36	Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy. Frontiers in Endocrinology, 2017, 8, 331.	1.5	12

#	Article	IF	CITATIONS
37	A Tollâ€like receptor 2 genetic variant modulates occurrence of bacterial infections in patients with sickle cell disease. British Journal of Haematology, 2019, 185, 918-924.	1.2	12
38	Stem cell therapy for diabetes mellitus. Kidney International Supplements, 2011, 1, 94-98.	4.6	10
39	Teplizumab in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine, 2019, 381, 1879-1881.	13.9	10
40	DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes. Inflammation, 2019, 42, 449-462.	1.7	10
41	Emerging CAR T cell therapies: clinical landscape and patent technological routes. Human Vaccines and Immunotherapeutics, 2020, 16, 1424-1433.	1.4	10
42	Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease. Frontiers in Immunology, 2020, 11, 2041.	2.2	10
43	Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Frontiers in Oncology, 2021, 11, 665037.	1.3	10
44	Hypoxia priming improves in vitro angiogenic properties of umbilical cord derived-mesenchymal stromal cells expanded in stirred-tank bioreactor. Biochemical Engineering Journal, 2021, 168, 107949.	1.8	9
45	Caspase-mediated cleavage of the exosome subunit PM/Scl-75 during apoptosis. Arthritis Research and Therapy, 2007, 9, R12.	1.6	8
46	CMV-specific clones may lead to reduced TCR diversity and relapse in systemic sclerosis patients treated with AHSCT. Rheumatology, 2020, 59, e38-e40.	0.9	7
47	Metabolic and Pancreatic Effects of Bone Marrow Mesenchymal Stem Cells Transplantation in Mice Fed High-Fat Diet. PLoS ONE, 2015, 10, e0124369.	1.1	7
48	A Methodology for the Development of RESTful Semantic Web Services for Gene Expression Analysis. PLoS ONE, 2015, 10, e0134011.	1.1	7
49	Transplante de células-tronco hematopoéticas em doenças reumáticas parte 1: experiência internacional. Revista Brasileira De Reumatologia, 2005, 45, 229.	0.8	6
50	Immunophenotypic Analysis of CAR-T Cells. Methods in Molecular Biology, 2020, 2086, 195-201.	0.4	6
51	Autologous hematopoietic stem cell transplantation modifies specific aspects of systemic sclerosis-related microvasculopathy. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210848.	1.2	6
52	CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers. Methods in Molecular Biology, 2020, 2086, 1-10.	0.4	4
53	Autologous hematopoietic stem cell transplantation promotes connective tissue remodeling in systemic sclerosis patients. Arthritis Research and Therapy, 2022, 24, 95.	1.6	4
54	Ethics of Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus—Reply. JAMA - Journal of the American Medical Association, 2007, 298, 285.	3.8	3

#	Article	IF	CITATIONS
55	THU0501â€Hematopoietic Stem Cell Transplantation Increases Naive and Regulatory B Cells While Decreasing Memory B Cells in Systemic Sclerosis Patients. Annals of the Rheumatic Diseases, 2014, 73, 356.2-356.	0.5	3
56	Lower Insulin-Dose Adjusted A1c (IDAA1c) Is Associated With Less Complications in Individuals With Type 1 Diabetes Treated With Hematopoetic Stem-Cell Transplantation and Conventional Therapy. Frontiers in Endocrinology, 2019, 10, 747.	1.5	2
57	Short Communication: Human Bone Marrow Stromal Cells Exhibit Immunosuppressive Effects on Human T Lymphotropic Virus Type 1 T Lymphocyte from Infected Individuals. AIDS Research and Human Retroviruses, 2019, 35, 164-168.	0.5	2
58	Editorial: Immune Profile After Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: Where Do We Stand?. Frontiers in Immunology, 2019, 10, 3044.	2.2	2
59	Newly-Generated Regulatory B- and T-Cells Are Associated with Clinical Improvement and Reversal of Dermal Fibrosis in Systemic Sclerosis Patients after Autologous Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 4625-4625.	0.6	2
60	Autologous Hematopoietic Stem Cell Transplantation for Type I Diabetes Mellitus Blood, 2004, 104, 5224-5224.	0.6	2
61	Allogeneic haematopoietic stem cell transplantation resets T―and Bâ€cell compartments in sickle cell disease patients. Clinical and Translational Immunology, 2022, 11, e1389.	1.7	2
62	Thymus Rejuvenation After Autologous Hematopoietic Stem Cell Transplantation in Patients with Autoimmune Diseases. , 2019, , 295-309.		1
63	Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients. Frontiers in Immunology, 2021, 12, 774442.	2.2	1
64	Transplante de células-tronco hematopoéticas em doenças reumáticas. Parte 2: experiência brasileira e perspectivas futuras. Revista Brasileira De Reumatologia, 2005, 45, 301.	0.8	0
65	OP0010â€Autologous Hematopoietic Stem Cell Transplantation Increases T-Cell PD-1 Expression and Regulatory Mechanisms in Systemic Sclerosis Patients. Annals of the Rheumatic Diseases, 2015, 74, 67.3-68.	0.5	0
66	Mesenchymal Stromal Cells Promote a Sustained Increase of the CD69 Marker on Activated CD3+ Lymphocytes: Potential Immunomodulatory Role. Blood, 2008, 112, 2417-2417.	0.6	0
67	HLA-G Transference From Multipotent Mesenchymal Stromal Cells to Activated T-Lymphocytes Blood, 2009, 114, 3674-3674.	0.6	0
68	T Cell Repertoire Diversity of Sickle Cell Anemia Patients Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Conventional Treatments. Blood, 2016, 128, 4586-4586.	0.6	0